Oric Pharmaceuticals, Inc. (ORIC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$12.46

From 52W high−13.17%

Volume1.19M

Market cap$1.32B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$12.46

From 52W high

−13.17%

Volume

1.19M

Market cap

$1.32B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.4x

P/E (TTM)

—

RSI (14)

51.8

MomentumView details →

1D Return

+3.00%

YTD Return

+54.24%

SummaryUpdated Jun 1, 2026

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company went public in April 2020 and focuses on discovering and developing precision cancer therapies that target specific resistance mechanisms in oncology. ORIC operates as a research-driven organization that aims to overcome the challenges patients face when their cancers become resistant to existing treatments, including both chemotherapy and newer immunotherapy approaches.

Ask drillr about Oric Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−36.81%

ROA (TTM)

−34.68%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+28.57%

FCF YoY

+7.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+19.67%

EBITDA YoY

−2.29%

MomentumView details →

1D Return

+3.00%

YTD Return

+54.24%

1Y Return

+1.92%

RSI (14)

51.8

vs 50D SMA

−2.58%

vs 200D SMA

+14.22%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

13.19x

Quick Ratio

13.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

−5.75%

Beats (12Q)

7/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

1.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−140.35M

Op. CF (TTM)

−111.64M

Next earningsNov 12, 2026 →

Latest newsMore news →

Oric Pharmaceuticals, Inc. announced that it will host a conference call and webcast on October 23, 2026, to review enozertinib data presented at the Oric Pharmaceuticals, Inc..11h ago

ORIC Pharmaceuticals announced an agreement with Cancer Research UK under which Cancer Research UK will fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259, a CIP2A-targeted therapy, while ORIC retains an exclusive option to reacquire rights after Phase 1/2 data.14d ago

Similar companies

Inhibrx Biosciences, Inc.INBX Tyra Biosciences, Inc.TYRA First Tracks Biotherapeutics IncTRAX Taysha Gene Therapies, Inc.TSHA Rapport Therapeutics, Inc. Common StockRAPP Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK Find similar companies →

Latest newsMore news →

Oric Pharmaceuticals, Inc. announced that it will host a conference call and webcast on October 23, 2026, to review enozertinib data presented at the Oric Pharmaceuticals, Inc..11h ago ORIC Pharmaceuticals announced an agreement with Cancer Research UK under which Cancer Research UK will fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259, a CIP2A-targeted therapy, while ORIC retains an exclusive option to reacquire rights after Phase 1/2 data.14d ago